Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used for the treatment of moderate to severe Alzheimer's disease. It works by modulating glutamate signaling, which is thought to be dysregulated in Alzheimer's disease and contributes to excitotoxic neuronal damage.
| Property |
Value |
| Drug Class |
NMDA Receptor Antagonist |
| Approval Status |
FDA Approved (2000) |
| Brand Names |
Namenda, Namenda XR, Ebixa |
| Mechanism |
Low-affinity NMDA receptor antagonism |
| Route of Administration |
Oral (immediate and extended-release) |
| Half-life |
60-80 hours |
Memantine provides neuroprotection through unique mechanisms:
- NMDA Receptor Modulation: Low-affinity, uncompetitive blocking of NMDA receptors
- Pathology-Selective Action: Preferentially blocks pathologically overactive NMDA channels
- Normal Synaptic Function: Preserves normal glutamatergic transmission
- Calcium Homeostasis: Prevents excitotoxic calcium influx
- Anti-Excitotoxic Effects: Protects against glutamate-induced neuronal death
- Moderate to Severe AD: First-line treatment for moderate-severe stages
- Combination Therapy: Often combined with acetylcholinesterase inhibitors
- Cognitive Benefits: Improves cognition, function, and global status
- Extended-Release: Once-daily formulation improves compliance
- Vascular dementia
- Mild Cognitive Impairment (MCI)
- Parkinson's disease dementia
- Dementia with Lewy Bodies
- Frontotemporal dementia
- Traumatic brain injury
| Parameter |
Value |
| Bioavailability |
~100% |
| Protein Binding |
~45% |
| Metabolism |
Minimal (60% excreted unchanged) |
| Elimination |
Renal (primarily) |
| Time to Steady State |
~3 weeks |
- Dizziness
- Headache
- Constipation
- Confusion
- Hypertension (less common)
- Agitation
- Hallucinations
- Anxiety
- Depression
- Severe vomiting
- Seizures
- Pancreatitis (rare)
- Heart failure (rare)
| Interacting Drug |
Effect |
| Amantadine |
Additive NMDA blockade |
| Ketamine |
Additive effects (avoid) |
| Cimetidine |
May increase levels |
| Anticholinergics |
Additive cognitive effects |
- Reisberg et al. (2003): MEMANTINE-AD pivotal trial - significant benefits
- Tariot et al. (2004): Memantine + donepezil combination study
- Poirier et al. (2015): Meta-analysis confirming efficacy
- MEMD-Study: Memantine + Donepezil superior to either alone
- Standard of care: Memantine + cholinesterase inhibitor
- Well-tolerated in most patients
- Long half-life allows once-daily dosing
- No liver toxicity
- Preserves normal glutamatergic signaling
- Evidence for disease modification in some studies
- Available as combination product with donepezil (Namzaric)
- Modest efficacy (clinically meaningful but limited)
- Delayed onset of benefit (weeks to months)
- Not effective for mild AD
- May cause psychiatric symptoms
| Feature |
Memantine |
Donepezil |
Rivastigmine |
Galantamine |
| Target |
NMDA receptor |
AChE |
AChE |
AChE |
| Stage |
Moderate-Severe |
Mild-Severe |
Mild-Moderate |
Mild-Moderate |
| Efficacy |
Moderate |
Moderate |
Moderate |
Moderate |
| Combination |
Yes (with AChEIs) |
Yes (with memantine) |
No |
No |
- Early Intervention: Testing in MCI and early AD
- Combination Strategies: Triple therapy approaches
- Neuroprotection: Biomarker studies
- Delivery Systems: Transdermal formulations
- Biomarkers: Predicting responders
The study of Memantine Nmda Antagonist For Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Reisberg B, et al. "Memantine in moderate-to-severe Alzheimer's disease." N Engl J Med. 2003;348(14):1333-1341. PMID:12672860
- Tariot PN, et al. "Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial." JAMA. 2004;291(3):317-324. PMID:14734594
- McShane R, et al. "Memantine for dementia." Cochrane Database Syst Rev. 2006;(2):CD003154. PMID:16625572
- Parsons CG, et al. "Memantine: a NMDA receptor antagonist that improves cognition by rendering normal NMDA receptor transmission." J Neural Transm. 2007;114(2):203-213. PMID:17237754
- Lipton SA. "Paradigm shift in neuroprotective drug development: clinically tolerated NMDA modulation by low-affinity channel blockers." Lancet. 1999;354(9184):1388-1391. PMID:10543739
- Wenk GL, et al. "Memantine as a treatment for Alzheimer's disease: uncoupling efficacy from clinical response." CNS Spectr. 2006;11(4):272-275. PMID:16575408
- Kavirajan H, Schneider LS. "Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials." Lancet Neurol. 2007;6(9):782-792. PMID:17689146
- Gauthier S, et al. "Clinical benefits of memantine in everyday practice." Int J Geriatr Psychiatry. 2008;23(7):683-689. PMID:18213698